Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €65.34 EUR
Change Today -1.76 / -2.62%
Volume 420.0
ZEGA On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 10:45 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc-spons adr (ZEGA) Snapshot

Open
€67.35
Previous Close
€67.10
Day High
€68.05
Day Low
€65.34
52 Week High
04/23/15 - €68.29
52 Week Low
04/25/14 - €48.88
Market Cap
82.5B
Average Volume 10 Days
81.2
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
02/18/15
P/E TM
--
Dividend
€3.64
Dividend Yield
3.58%
Current Stock Chart for ASTRAZENECA PLC-SPONS ADR (ZEGA)

astrazeneca plc-spons adr (ZEGA) Details

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. As of December 31, 2014, it had 133 pipeline projects. The company markets its products through distributors and local representative offices. In addition, it engages in the insurance and reinsurance underwriting business. The company has collaboration agreements with Immunocore Limited, Kyowa Hakko Kirin Co., Ltd., Advaxis Inc., and Pharmacyclics Inc. and Janssen Research & Development, LLC. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

57,500 Employees
Last Reported Date: 03/10/15
Founded in 1992

astrazeneca plc-spons adr (ZEGA) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.1M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 1.7M GBP
Compensation as of Fiscal Year 2014.

astrazeneca plc-spons adr (ZEGA) Key Developments

AstraZeneca PLC Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2015; Reiterates Earnings Guidance for the Year 2015

AstraZeneca PLC announced unaudited consolidated financial results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of $6,057 million against $6,460 million a year ago. Operating profit was $933 million against $836 million a year ago. Profit before tax was $678 million against $638 million a year ago. Profit attributable to owners of the parent was $550 million against $504 million a year ago. Earnings per share basic and diluted were $0.44 against $0.40 a year ago. Net cash used in operating activities was $72 million compared with net cash from operating activities of $1,187 million a year ago. Purchase of property, plant and equipment was $227 million compared to $183 million a year ago. Purchase of intangible assets was $848 million compared to $545 million a year ago. Net debt as at March 31, 2015 was $6,373 million compared to $4,833 million as of March 31, 2014. Core operating profit was down 4% to $1,805 million. The Company reiterates the guidance for the year 2015. For the year 2015, the company’s total revenue is expected to decline by mid-single-digit percent at CER and core EPS is expected to increase by low single-digit percent at CER.

Innate Pharma and AstraZeneca Announce Global Agreement for IPH2201 in Immuno-oncology

Innate Pharma S.A. announced that it has signed a co-development and commercialization agreement with AstraZeneca, along with MedImmune, its global biologics research and development arm, to accelerate and broaden the development of Innate Pharma's proprietary anti-NKG2A antibody, IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune. Currently in Phase II development, IPH2201 is a potential first-in-class humanized IgG4 antibody. NKG2A is a checkpoint receptor that inhibits the anti-cancer functions of Natural Killer and cytotoxic T-cells. The financial terms of the signed agreement include cash payments of up to $1.275 billion to Innate Pharma as well as double digit royalties on sales. The initial payment is $250 million, which includes a consideration for the exclusive global rights to AstraZeneca to co-develop and commercialize IPH2201 in combination with MEDI4736 and access to IPH2201 in monotherapy and other combinations in certain areas. AstraZeneca will pay to Innate a further $100 million prior to initiation of Phase III development, as well as additional regulatory and sales-related milestones of up to $925 million. AstraZeneca will book all sales and will pay Innate double-digit royalties on net sales. The arrangement includes the right for Innate to co-promote in Europe for a 50% profit share in the territory. The initial development plan includes: Phase II combination clinical trials with MEDI4736 in solid tumors; multiple Phase II trials planned by Innate to study IPH2201 both as monotherapy and in combination with currently approved treatments across a range of cancers; and the development of associated biomarkers. The combination of IPH2201 with MEDI4736 adds to the broad programme of immuno-oncology combination trials that AstraZeneca and MedImmune have planned and underway. The studies aim to address multiple immune pathways, harnessing AstraZeneca's own extensive pipeline and working in partnership to explore the significant potential of immunotherapies in transforming the way cancer patients are treated. The transaction is subject to customary terms and conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and is expected to become effective in the second quarter of 2015.

Astrazeneca Announces Positive Clinical Trial Evidence for its Investigational Non-Small-Cell Lung Cancer Treatment AZD9291

AstraZeneca announced on 17 April positive clinical trial evidence for its investigational non-small-cell lung cancer (NSCLC) treatment AZD9291. The company reported that AZD9291, which is currently studied in the Phase I/II AURA study, showed a median progression free survival of 13.5 months in NSCLC patients with advanced epidermal growth factor receptor mutation-positive who also have the T790M resistance mutation. Data were presented at the European Lung Cancer Conference 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEGA:GR €65.34 EUR -1.76

ZEGA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $66.07 USD +1.82
BASF SE €91.67 EUR +0.86
Biogen Inc $401.71 USD -28.57
Celgene Corp $118.71 USD +2.62
Eli Lilly & Co $71.58 USD -0.82
View Industry Companies
 

Industry Analysis

ZEGA

Industry Average

Valuation ZEGA Industry Range
Price/Earnings 74.6x
Price/Sales 3.5x
Price/Book 4.7x
Price/Cash Flow 74.5x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC-SPONS ADR, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.